SG11201806338SA - Use of cd24 proteins for treating leptin-deficient conditions - Google Patents
Use of cd24 proteins for treating leptin-deficient conditionsInfo
- Publication number
- SG11201806338SA SG11201806338SA SG11201806338SA SG11201806338SA SG11201806338SA SG 11201806338S A SG11201806338S A SG 11201806338SA SG 11201806338S A SG11201806338S A SG 11201806338SA SG 11201806338S A SG11201806338S A SG 11201806338SA SG 11201806338S A SG11201806338S A SG 11201806338SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- pct
- leptin
- deficient conditions
- Prior art date
Links
- 102000016267 Leptin Human genes 0.000 title abstract 3
- 108010092277 Leptin Proteins 0.000 title abstract 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 3
- 229940039781 leptin Drugs 0.000 title abstract 3
- 230000002950 deficient Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 abstract 2
- 102100038081 Signal transducer CD24 Human genes 0.000 abstract 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290202P | 2016-02-02 | 2016-02-02 | |
| PCT/US2017/016120 WO2017136492A1 (en) | 2016-02-02 | 2017-02-02 | Use of cd24 proteins for treating leptin-deficient conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806338SA true SG11201806338SA (en) | 2018-08-30 |
Family
ID=59500202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806338SA SG11201806338SA (en) | 2016-02-02 | 2017-02-02 | Use of cd24 proteins for treating leptin-deficient conditions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10799558B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3411062B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6938835B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20180120145A (cg-RX-API-DMAC10.html) |
| CN (1) | CN109069583B (cg-RX-API-DMAC10.html) |
| CA (1) | CA3012466A1 (cg-RX-API-DMAC10.html) |
| SG (1) | SG11201806338SA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017136492A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630158B1 (en) * | 2017-05-22 | 2022-07-13 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |
| US20210046154A1 (en) * | 2018-03-05 | 2021-02-18 | Oncoimmune, Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| TW202015753A (zh) * | 2018-06-04 | 2020-05-01 | 美商昂科免疫公司 | 以cd24預防及治療移植物抗宿主病及黏膜炎之方法 |
| WO2020163529A1 (en) | 2019-02-06 | 2020-08-13 | Oncoimmune, Inc. | Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072325A1 (en) * | 2000-03-29 | 2001-10-04 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| JP2007504842A (ja) * | 2003-05-29 | 2007-03-08 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| CA2851602C (en) | 2011-08-30 | 2020-07-14 | Academisch Medisch Centrum | Method for preventing and/or treating insulin resistance |
| WO2014071379A1 (en) * | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Dosing and administration of oligonucleotide cancer therapies |
-
2017
- 2017-02-02 US US16/074,726 patent/US10799558B2/en not_active Expired - Fee Related
- 2017-02-02 CA CA3012466A patent/CA3012466A1/en not_active Abandoned
- 2017-02-02 WO PCT/US2017/016120 patent/WO2017136492A1/en not_active Ceased
- 2017-02-02 KR KR1020187022125A patent/KR20180120145A/ko not_active Ceased
- 2017-02-02 EP EP17748111.6A patent/EP3411062B1/en active Active
- 2017-02-02 SG SG11201806338SA patent/SG11201806338SA/en unknown
- 2017-02-02 CN CN201780008474.2A patent/CN109069583B/zh not_active Expired - Fee Related
- 2017-02-02 JP JP2018539976A patent/JP6938835B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-12 US US17/067,929 patent/US20210162006A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019506408A (ja) | 2019-03-07 |
| US20190038716A1 (en) | 2019-02-07 |
| CN109069583A (zh) | 2018-12-21 |
| US20210162006A1 (en) | 2021-06-03 |
| JP6938835B2 (ja) | 2021-09-22 |
| WO2017136492A1 (en) | 2017-08-10 |
| CA3012466A1 (en) | 2017-08-10 |
| CN109069583B (zh) | 2021-09-21 |
| KR20180120145A (ko) | 2018-11-05 |
| EP3411062A4 (en) | 2019-09-25 |
| EP3411062A1 (en) | 2018-12-12 |
| US10799558B2 (en) | 2020-10-13 |
| EP3411062B1 (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201810331YA (en) | Single chain variable fragment cd3 binding proteins | |
| SG11201804696RA (en) | Techniques for metadata processing | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |